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Nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer. Approximately 70% of patients with newly diagnosed
NPC present with locally advanced disease. Phase III clinical trials support the addition of chemotherapy to radiotherapy for the initial
treatment of these patients. Once metastatic disease develops, practices become varied. Further experience needs to be gained with
both targeted therapies and immunotherapy to gauge whether they will improve treatment outcomes in NPC.
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Nasopharyngeal carcinoma (NPC) is a distinct type of head and
neck cancer that differs from other malignancies of the upper
aerodigestive tract with respect to epidemiology, pathology,
clinical presentation and responses to treatment. Outside of
endemic areas such as Southeast Asia, this type of tumour is
extremely rare with an incidence of less than 1/100000 (Fandi et al,
1994). Patients with stage I and II disease have a high rate of cure
with radiotherapy (RT) alone, while the prognosis for those with
distant metastatic spread remains poor. Approximately 70% of
patients with newly diagnosed NPC present with locally advanced,
nonmetastatic stage III or IV disease. For this patient population,
surgery has a limited role and RT delivered in combination with
chemotherapy has become the standard of care. However, the
timing, dosing, duration and optimal regimens of chemotherapy
drugs to be combined with RT remain controversial. Several
randomised trials have evaluated neoadjuvant, concurrent and
adjuvant chemotherapy in different combinations with RT. This
review focuses on the evidence to support treatment of locally
advanced NPC, and provides an update of promising therapies that
are on the horizon.
THE ADDITION OF CHEMOTHERAPY TO RT FOR
LOCALLY ADVANCED NPC
A Medline and American Society of Clinical Oncology abstract
search was conducted using the keywords ‘nasopharyngeal cancer/
carcinoma’ and ‘radiotherapy/radiation therapy’ and ‘chemother-
apy’. Articles and abstracts were eligible for review if patients were
randomly assigned to receive chemotherapy and RT or RT alone.
There are 11 published papers and four abstracts, which present
the results of 13 randomised clinical trials comparing chemother-
apy with RT to RT alone in patients with locally advanced NPC
(Tables 1 and 2). Only studies published in the English literature
were included in this review.
Neoadjuvant chemotherapy
Four trials have assessed the role of neoadjuvant chemotherapy
followed by RT vs RT alone (VUMCA 1996; Chua et al, 1998; Ma
et al, 2001; Hareyama et al, 2002). The VUMCA I trial treated 339
patients in the neoadjuvant therapy arm with cisplatin, epirubicin
and bleomycin. After a median follow-up duration of 49 months,
this trial failed to show an overall survival (OS) advantage in the
neoadjuvant therapy arm but did report a statistically significant
increase in 3-year disease-free survival (DFS) rates (52 vs 32%,
interpolated). However, a treatment-related toxic death rate of 8%
was encountered in the neoadjuvant therapy arm in this multi-
centre trial. In a small trial, Hareyama et al randomised 80 patients
to two cycles of cisplatin and 5-fluorouracil administered prior to
RT vs RT alone. Trends towards improved 5-year DFS and OS were
demonstrated in the neoadjuvant therapy arm, but statistically
significant differences were not achieved after a median follow-up
period of 49 months. In their initial reporting after a median
follow-up duration of 30 months, Chua et al showed similar results
with their neoadjuvant combination of cisplatin and epirubicin.
Again, trends towards improved OS and DFS were seen in the
neoadjuvant therapy arm, but the results were not statistically
significant. Lastly, Ma et al compared two to three cycles of
bleomycin, cisplatin and 5-fluorouracil followed by RT to RT alone
and showed a statistically significant prolongation of DFS in the
chemotherapy group (59 vs 49% at 5 years). A trend towards OS
was observed in the neoadjuvant arm of the trial. Updated
combined data from these two latter trials (Chua DTT et al, 2004)
on 784 patients, after a median follow-up period of 67 months,
reported a statistically significant improvement in 5-year DFS (51
vs 43%) favouring the neoadjuvant therapy arm, but not in 5-year
OS (62 vs 58%). Reductions in both locoregional and distant
failures were observed. Although it has been suggested by the
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documented in a phase III randomised trial using neoadjuvant
chemotherapy followed by RT.
Concurrent chemotherapy
Two trials have compared concurrent chemotherapy and RT vs RT
alone (Chan et al, 2002; Lin et al, 2003). Lin et al randomised
patients to concurrent chemoradiotherpy vs RT alone. Using the
1992 American Joint Committee on Cancer (AJCC) staging system,
all 284 patients had either stage III or IV disease. Patients
randomised to the concurrent chemotherapy arm of the study
received two cycles of cisplatin mixed with 5-fluorouracil
administered as a 96-h continuous infusion during weeks 1 and
5 of RT. The 5-year OS rates for the chemotherapy arm were 72%
compared with 54% in the control arm; the 5-year DFS rates were
72 vs 53%, respectively. Both comparisons were statistically
significant. In a similar study, Chan et al randomised patients to
adjuvant weekly low-dose cisplatin and standard RT vs RT alone.
Over 90% of their patients were Ho tumour stage III or IV. The 2-
year DFS in the chemotherapy arm was 76% compared to 69% in
the RT alone group, which did not achieve statistical significance,
and OS was not reported in the initial analysis after a follow-up
period of 33 months. Updated data from the Chan et al (2004)
study, after a median follow-up duration of 65 months, reported 5-
year DFS of 60 vs 52% and 5-year OS of 70 vs 59%, both reaching
borderline statistical significance (P¼0.06 and 0.05, respectively),
in favour of the concurrent chemoradiotherapy arm. Reclassifica-
tion of the 350 patients on this trial using the 1997 AJCC staging
system revealed that over 70% were of stage III and IV. Subgroup
analysis demonstrated that patients with T3 and T4 disease derived
the most benefit. Based on these two randomised trials, patients
with advanced locoregional NPC benefit from concurrent chemor-
adiotherapy over RT alone.
Adjuvant chemotherapy
The first published randomised trial in locoregional NPC
compared adjuvant chemotherapy after RT to RT alone (Rossi
et al, 1988). The regimen used in this 4-year multicentre
randomised trial was vincristine, cyclophosphamide and adriamy-
cin. Patients were treated with 6 monthly cycles of treatment
following their RT. Analysis of the patient data at 4 years failed to
show a statistically significant change in DFS or OS between the
two groups. As well, interestingly, the pattern of failure in both
groups was similar with distant metastasis accounting for 50% of
Table 1 Randomised trials of chemotherapy with RT vs RT alone in locally advanced NPC
Author and year No. of pts. Treatment arms
Neoadjuvant chemotherapy+RT vs RT alone
VUMCA (1996) a: 171 a: B 15mg D1, 12mgm
 2d
 1 D1–5, E 70mgm
 2 D1, and P 100mgm
 2 D1 every 21 days 3-RT
b: 168 b: RT
Hareyama et al (2002) a: 40 a: P 80mgm
 2 D1 and F 800mgm
 2d
 1 D2–5 every 21days 2-RT
b: 40 b: RT
Chua et al (1998) a: 167 a: P 60mgm
 2 D1 and E 110mgm
 2 D1 every 21 days 2–3-RT
b: 167 b: RT
Ma et al (2001) a: 224 a: P 100mgm
 2 D1, B 10mgm
 2 D1 and 5, and F 800mgm
 2d
 1 D1–5 every 21 days 2–3-RT
b: 225 b: RT
Concurrent chemotherapy+RT vs RT alone
Lin et al (2003) a; 141 a: P 20mgm
 2d
 1 D1–4 and F 800mgm
 2d
 1 D1–4 on weeks 1, 5+RT
b: 143 b: RT
Chan et al (2002, 2004) a: 174 a: P 40mgm
 2 weekly+RT
b: 176 b: RT
Adjuvant chemotherapy+RT vs RT alone
Rossi et al (1988) a: 113 a: RT-V 1.2mgm
 2 D1, C 200mgm
 2d
 1 D1–4, and A 40mgm
 2 D1 every 28 days 6
b: 116 b: RT
Chi et al (2002) a: 77 a: RT-P2 0m gm
 2 D1, F 2200mgm
 2 D1, and L 120mgm
 2 D1 weekly 9
b: 77 b: RT
Neoadjuvant and adjuvant chemotherapy+RT vs RT alone
Chan et al (1995) a: 37 a: P 100mgm
 2 D1 and F 1000mgm
 2d
 1 D2–4 every 21 days 2-RT-P 100mgm
 2 D1
and F 1000mgm
 2d
 1 D2–4 every 21 days 4
b: 40 b: RT
Concurrent and adjuvant chemotherapy+RT vs RT alone
Al-Sarraf et al (1998, 2001) a: 93 a: P 100mgm
 2 D1, 22, 43+RT-P8 0m gm
 2 D1 and F 1000mgm
 2d
 1 D1–4 weeks 11, 15, 19
b: 92 b: RT
Wee et al (2004) a: 111 a: P 25mgm
 2d
 1 D1–4 weeks 1, 4, 7+RT-P2 0m gm
 2d
 1 D1–4 and F 1000mgm
 2d
 1 D1–4 weeks 11, 15, 19
b: 109 b: RT
Lee et al (2004) a: 172 a: P 100mgm
 2 D1, 22, 43+RT-P8 0m gm
 2 D1 and F 1000mgm
 2d
 1 D1–4 weeks 11, 15, 19
b: 176 b: RT
Kwong et al (2004) a1:5 7 a 1: UFT 600mgd
 1+RT-P 100mgm
 2 D1 and F 1000mgm
 2d
 1 D1–3 alternating with V 2mg, B 30mg,
and M 150mgm
 2 every 21 days 6
a2:5 3 a 2: UFT 600mgd
 1+RT
a3:5 4 a 3:R T -P 100mgm
 2 D1 and F 1000mgm
 2d
 1 D1–3 alternating with V 2mg, B 30mg, and M 150mgm
 2
every 21 days 6
b: 55 b: RT
NPC¼nasopharyngeal carcinoma; RT¼radiotherapy; P¼cisplatin; F¼fluorouracil; B¼bleomycin; E¼epirubicin; V¼vincristine; C¼cyclophosphamide; A¼adriamycin;
L¼leucovorin; M¼methotrexate; UFT¼uracil–tegafur; a(a1,a 2,a 3)¼combined therapy arm; b¼radiotherapy alone arm; d¼day; D¼day; pts.¼patients.
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active agent in NPC, cisplatin, has been omitted from their
regimen. A second adjuvant trial did incorporate cisplatin with 5-
fluorouracil and leucovorin postradiation in patients with locally
advanced NPC (Chi et al, 2002). The chemotherapy delivered in the
adjuvant arm consisted of the three agents given as a 24-h infusion,
for 9 weekly cycles. At 5 years, there was no noted statistically
different OS or DFS between the two groups of patients. Based on
these two trials, adjuvant chemotherapy alone cannot be
recommended for patients with advanced NPC.
Neoadjuvant and adjuvant chemotherapy
Only one phase III trial of 77 patients has evaluated the combined
role of neoadjuvant and adjuvant chemotherapy (Chan et al, 1995).
Neoadjuvant and adjuvant chemotherapy consisted of two and
four cycles of cisplatin and 5-fluorouracil, respectively. After a
follow-up duration of 28.5 months, no significant difference has
been observed in either the DFS or OS.
Concomitant and adjuvant chemotherapy
A major breakthrough in the management of locally advanced NPC
came about in 1998 with the publication of the phase III
randomised Intergroup study 0099 (Al-Sarraf et al, 1998). Both
arms of the study received identical RT, while the chemotherapy
arm of the study received both concomitant and adjuvant
chemotherapy. Cisplatin as a single agent was administered on
days 1, 22 and 43 of the concurrent RT, and three adjuvant cycles
of cisplatin with 5-fluorouracil were given monthly after comple-
tion of chemoradiotherapy. At 3 years, the DFS was 69% in the
chemotherapy group and 24% in the RT alone arm. Their survival
rates at 3 years were 78 vs 47%, favouring chemotherapy. Updated
analysis at 5 years (Al-Sarraf et al, 2001) confirms the benefit of
treatment with 5-year DFS rates of 58 vs 29% and 5-year OS rates
of 67 vs 37%, both favouring the combined therapy arm. The
National Cancer database has been analysed for changing patterns
of practice since the first published results of the Intergroup 0099
study data in 1998. Of all patients enrolled in the database and
matching the eligibility criteria of the Intergroup 0099 study, only
Table 2 OS and DFS of randomised trials of chemotherapy with RT vs RT alone in locally advanced NPC
Author Treatment arm OS DFS Median F/U (mo)
Neoadjuvant chemotherapy+RT vs RT alone
VUMCA (1996) a 3yr – 60% 3yr – 52% *Po0.01 49
b 54% 32%
Hareyama et al (2002) a 5yr – 60% 5yr – 55% 49
b 48% 43%
Chua et al (1998) a 3yr – 78% 3yr – 48% 30
b 71% 42%
Ma et al(2001) a 5yr – 63% 5yr – 59% *P¼0.05 62
b 56% 49%
Chua et al(2004)
a a 5yr – 64% *P¼0.029 5yr – 51% *P¼0.014 67
b 58% 43%
Concurrent chemotherapy+RT vs RT alone
Lin et al(2003) a 5yr – 72% *Po0.01 5yr – 72% *Po0.01 65
b 54% 53%
Chan et al(2002, 2004) a N/A 2yr – 76% 33
b N/A 69%
a 5yr – 70% *Po0.05 5yr – 60% 65
b 59% 52%
Adjuvant chemotherapy+RT vs RT alone
Rossi et al(1988) a 5yr – 55% 5yr – 54% 49.5
b 61% 50%
Chi et al(2002) a 4yr – 59% 4yr – 58% 43
b 67% 56%
Neoadjuvant and adjuvant chemotherapy+RT vs RT alone
Chan et al(1995) a 2yr – 80% 2yr – 68% 28.5
b 81% 72%
Concurrent and adjuvant chemotherapy+RT vs RT alone
Al-Sarraf et al(1998, 2001) a 3yr – 76% *Po0.001 3yr – 66% *Po0.001 32.4
b 46% 26%
a 5yr – 67% *Po0.001 5yr – 58% *Po0.001 60
b 37% 29%
Wee et al(2004) a 2yr – 85% *P¼0.02 2yr – 76% N/A
b 77% 62%
Lee et al(2004) a 3yr – 77% 3yr – 67% 25
b 76% 61%
Kwong et al(2004) a1 3yr – 89% 3yr – 70% 32.5
a2 84% 69%
a3 71% 54%
b 83% 61%
*Statistically significant result (Pp0.05). a(a1,a 2,a 3)¼combined therapy arm; b¼radiotherapy alone arm; OS¼overall survival; DFS¼disease-free survival;
NPC¼nasopharyngeal carcinoma; RT¼radiotherapy; N/A¼not applicable; yr¼year; mo¼months.
aThis reference is an updated analysis of patients from Chua et al
(1998) and Ma et al (2001).
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since the publication of the data, 65% of these patients have
received concurrent and adjuvant chemotherapy (Hoffman et al,
2004).
One-quarter of all patients treated on the Intergroup 0099
protocol had World Health Organization (WHO) stage I histology
(keratinising squamous cell carcinoma). A phase III randomised
trial using a similar chemotherapy and RT plan has been
completed, with enrolment restricted to patients with WHO type
IIa (nonkeratinising squamous cell carcinoma) and IIb (undiffer-
entiated carcinoma) histologies (Wee et al, 2004). The chemother-
apy regimen differed slightly from the Intergroup 0099 trial with
the dose of cisplatin given in divided doses rather than one dose,
but the total dose remained the same. The 2-year DFS and OS rates
were statistically significant and favoured the use of chemotherapy.
The Hong Kong NPC Study Group (Lee et al, 2004) randomised
patients with nonkeratinising or undifferentiated NPC to the
identical Intergroup 0099 regimen. On preliminary analysis after a
median follow-up period of 2.3 years, the trends favoured the
addition of chemotherapy with respect to DFS, but no benefit in OS
was noted. Locoregional control was improved with the addition of
chemotherapy.
In addition to the three trials mentioned above, which compared
concurrent chemoradiotherapy plus adjuvant chemotherapy vs RT
alone, a factorial study of four different regimens has been
published (Kwong et al, 2004). This study assessed the combina-
tion of RT alone vs three other schemas: RT with adjuvant
chemotherapy, concurrent chemoradiotherapy and lastly, concur-
rent chemoradiotherapy followed by adjuvant chemotherapy. UFT
(uracil and tegafur in 4:1 molar ratio) was used as the concurrent
chemotherapy agent, while the adjuvant chemotherapy protocol
consisted of alternating cycles of cisplatin/5-fluorouracil with
vincristine/bleomycin/methotrexate. Although a trend towards
improved DFS and OS was noted with the addition of concurrent
chemotherapy, it did not reach statistical significance at 3 years. In
assessing distant metastases rates, a significant reduction was
attributable to concurrent chemotherapy. In this study, adjuvant
chemotherapy did not improve outcome.
SUMMARY OF EVIDENCE: THE ADDITION OF CHE-
MOTHERAPY TO RT FOR LOCALLY ADVANCED NPC
Based on published randomised trials that addressed the value of
adding chemotherapy to RT in locally advanced NPC, several
conclusions may be drawn. It is important to note that these trials
were completed over a 16-year time span (1988–2004) in different
geographic areas. As such, several tumour staging systems and
improved diagnostic techniques have been utilised, which might
have contributed to a phenomenon of stage migration (Feinstein
et al, 1985). That withstanding, the timing of chemotherapy
appears to impact on clinical outcome. Concurrent chemotherapy
delivered with RT has consistently produced a survival benefit
when compared to RT alone, achieving 5-year OS rates of about
70% with combined modality therapy in patients with nonmeta-
static stage III and IV disease.
The addition of further chemotherapy to concurrent chemor-
adiotherapy, delivered in a neoadjuvant or adjuvant sequence,
might further augment disease control. Reductions in both
locoregional and distant failures have been reported with the
addition of chemotherapy to RT, when delivered using validated
regimens in adequate dosages. In reviewing the 13 randomised
trials, chemotherapy compliance rates differed dramatically
depending on the timing of therapy. In the neoadjuvant setting,
87–100% of patients received the prescribed cycles of chemother-
apy, while 44–93% of patients scheduled for concurrent che-
motherapy received their planned cycles. Even fewer, 14–55% of
patients, completed their planned adjuvant chemotherapy. Clearly,
chemotherapy dose intensity is most optimally maintained in the
induction setting. This disparity in dose intensities may partially
explain the lack of benefit associated with the administration of
adjuvant chemotherapy alone. Treatment strategies to optimise
chemotherapy delivery to achieve locoregional and distant control
should utilise this information and consider the combination of
induction chemotherapy followed by concurrent therapy. Incor-
poration of newer, less toxic and more effective anticancer agents
such as gemcitabine, the taxanes or molecular targeted agents into
combined modality regimens warrant continual exploration in
locally advanced NPC. Collection of accurate toxicity data,
especially those related to nutritional status, salivary and
swallowing functions, ototoxicity, neuropathy and other late side
effects, is vital to the planning of appropriate remedies.
RT TECHNIQUES FOR LOCALLY ADVANCED NPC
Tumour control of NPC has been highly correlated with the RT
dose delivered to the tumour. In the above-mentioned randomised
trials, RT dosing is summarised in Table 3. The dosing in all
studies is similar and most are using a split field technique with
two lateral opposed facial fields and an anterior field if necessary.
A few studies enrolled patients and treated them with hyper-
fractionated RT twice per day, but the majority of patients in these
studies still received conventional fractionation. Only one study
included intracavitary brachytherapy for patients with persistent
local disease (Chan et al, 2002).
In order to achieve tumour control for carcinoma of the
nasopharynx, dosing of greater than 67 Gray (Gy) is required;
however, better technical accuracy of RT delivery can also improve
upon disease control. In 1998, the use of three–dimensional (3D)
intensity-modulated RT (IMRT) for NPC was implemented at the
Memorial Sloan-Kettering Cancer Centre. Initial treatment re-
ported an increased target dose delivery from 67.0 to 77.3Gy with
IMRT as compared to conventional treatment methods. Dose to
normal structures such as the spinal cord, mandible, temporal
lobes and parotid glands all decreased with IMRT (Hunt et al,
2001). A 2-year follow-up of the initial 39 patients treated with
IMRT confirms a local relapse-free survival (LRFS) of 97 vs 78% in
historical controls treated with conventional technique with a 3D
boost, suggesting an improved locoregional control with IMRT
(Wolden et al, 2002).
The University of California – San Francisco has also extensively
studied the use of IMRT in the treatment of NPC (Sultanem et al,
2000; Xia et al, 2000; Lee et al, 2002). Initially, IMRT treatment
plans were compared with conventional treatment plans for a case
of locally advanced NPC. Their planning confirmed that IMRT
techniques improved tumour target coverage and spared sensitive
normal tissue structures. Subsequently, 35 patients were treated
with IMRT for NPC. In all, 72% of these patients had 1997 AJCC
stage III or IV disease. At 22 months of follow-up, no local or
regional failures had been documented. This local control was
attributable to improved tumour target coverage, increased total
dose and increased dose per fraction to the tumour target. The
mean dose delivered to the tumour target was 75.8Gy. Follow-up at
31 months with a total of 67 patients confirmed the above and
reported only one local recurrence at the primary site. The vast
majority of failures in this series were attributed to distant
metastases. Of note, in this series, 75% of the patients did receive
concurrent and adjuvant chemotherapy as per the Intergroup
protocol 0099 regimen. The Prince of Wales Hospital (PWH)
experience in Hong Kong further confirms the benefits of IMRT. In
treating 63 newly diagnosed patients with NPC (stage I–IV
disease), a 3-year LRFS of 92% and OS of 90% are observed (Kam
et al, 2004).
Aside from documenting improved LRFS and OS with IMRT,
both the UCSF and PWH experiences confirm favourable toxicity
Review of nasopharyngeal carcinoma
M Agulnik and LL Siu
802
British Journal of Cancer (2005) 92(5), 799–806 & 2005 Cancer Research UKprofiles with IMRT. In spite of the increased dose, no increase in
complication was reported, likely attributable to the reduced
volumes to normal structures irradiated. Xerostomia is the most
common side effect experienced by patients treated with conven-
tional two-dimensional (2D) RT for NPC. Up to 97% of treated
patients have reported xerostomia as a complication of therapy
(Talmi et al, 2002). The UCSF data report no chronic xerostomia at
2 years, while the PWH experience reports 23% grade 2–3
xerostomia at 2 years with further decrease to 17% at 2 years in the
subset of patients treated with less than 31Gy to the parotid gland.
Although large randomised studies are not available to confirm
the advantage of IMRT over conventional 2D and 3D RT
techniques, the initial data are impressive in both locoregional
disease control and reduced toxicities. A role for IMRT as a
standard of care in the treatment of NPC is foreseeable. Aside from
IMRT, other techniques are being explored in both early-stage and
advanced NPC to improve upon locoregional response rates while
limiting toxicities. Both high-dose-rate intracavitary brachyther-
apy and stereotactic radiosurgical boost have been shown to
increase locoregional control rates when given as an adjuvant to
external beam RT (Pai et al, 2002; Le et al, 2003; Lu et al, 2004).
Given the preliminary data afforded by these phase II studies, the
future direction of RT in the treatment of NPC will certainly be a
move away from 2D RT to the adoption of 3D RT with IMRT, while
a more defined role for stereotactic radio surgery and intracavitary
brachytherapy in the management of locally advanced NPC still
needs to be established.
MOLECULAR TARGETED THERAPY
Recurrent or metastatic NPC remains largely an incurable disease,
although there have been reports of long-term survivors among
those who achieved complete responses to conventional che-
motherapy (Fandi et al, 2000). Combinations of cytotoxic
chemotherapeutic agents with antitumour activity, such as the
platinums, 5-fluorouracil, methotrexate, anthracyclines, gemcita-
bine and taxanes, typically yield high response rates of limited
duration, and are associated with normal tissue toxicity. At the
Princess Margaret Hospital, gemcitabine-based therapy has been
adopted as first-line therapy for recurrent or metastatic NPC, with
response rates of 34%, as a single agent among platinum-refractory
patients, or 64% when used in combination with cisplatin among
platinum-sensitive patients. Median duration of response was 17
and 24 weeks, and 1-year survival rates were 48 and 69%,
respectively (Ma et al, 2002) In order to maximise the proportion
of long-term survivors among patients with recurrent or metastatic
NPC, better systemic agents are needed to increase the likelihood
of complete responses. With a potentially superior therapeutic
index, molecular targeted agents represent exciting compounds,
which may complement the use of conventional chemotherapy in
this disease.
Several molecular targets have been identified in tumour
specimens of patient with NPC. Expression or overexpression of
the following receptors has been evaluated in NPC: epidermal
growth factor receptor (EGFR), vascular endothelial growth factor
(VEGF), c-KIT and c-erbB-2 (HER2). To date, no reports of
mutational analyses of any of these molecular targets have been
published.
A retrospective study was performed to assess the correlation
between the expression of EGFR and treatment outcome in
patients with advanced stage disease (Chua DT et al, 2004). All
patients in this group were treated with induction chemotherapy
followed by RT. Of the specimens tested, 89% of the cases
demonstrated EGFR expression. The extent and intensity of the
staining did not correlate with tumour burden or extent of disease.
Table 3 Initial RT dose and schedule of randomised trials of chemotherapy with RT vs RT alone in locally advanced NPC
Author Weekly fractions Primary tumour dose Involved nodes dose Remaining nodal area (Gy)
Neoadjuvant chemotherapy+RT vs RT alone
VUMCA (1996) 5 2Gyd
 1 65–70Gy 65Gy 50
Hareyama et al (2002) 5 2.0Gyd
 1 or
4 2.2Gyd
 1
66–68Gy 66–68Gy 50
Chua et al (1998) 5 2Gyd
 1 (n¼110) or
hypofractionated (n¼176)
66–70Gy (36%)
470–74Gy (64%)
60–66Gy (82.5%)
466–76Gy (17.5%)
60
Ma et al (2001) 5 2.0Gyd
 1 68–72Gy 60–62Gy 50
Concurrent chemotherapy+RT vs RT alone
Lin et al (2003) 5 2.0Gyd
 1 (n¼240) or
hyperfractionated (n¼44)
70–74Gy 70–74Gy 50–60
Chan et al (2002, 2004) 5 2Gyd
 1 66Gy N/A N/A
Adjuvant chemotherapy+RT vs RT alone
Rossi et al (1988) 1.8Gyd
 1 (n¼103) or
hyperfractionated (n¼13)
60–70Gy 60–70Gy 50
Chi et al (2002) 5 1.8–2.0Gyd
 1 70–72Gy 70–72Gy 50
Neoadjuvant and adjuvant chemotherapy+RT vs RT alone
Chan et al (1995) N/A 66Gy7boost 58Gy+7.5Gy boost 58
Concurrent and adjuvant chemotherapy+RT vs RT alone
Al-Sarraf et al (1998, 2001) 5 1.8–2.0Gyd
 1 70Gy 66–70Gy 50
Wee et al (2004) 2.0Gyd
 1 70Gy N/A N/A
Lee et al (2004) 5 2.0Gyd
 1 66Gy 66Gy N/A
Kwong et al (2004) 4 2.5Gyd
 1 to
40Gy then
5 2.5Gyd
 1 or
62.5Gy 62.5Gy N/A
5 2.0Gyd
 1 68Gy 66Gy N/A
Gy¼Grays; d¼day; N/A¼not applicable; RT¼radiotherapy; NPC¼nasopharyngeal carcinoma; a(a1,a 2,a 3)¼combined therapy arm, b¼radiotherapy alone arm.
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stained positive for EGFR had a reduced survival and increased
risk of locoregional failure compared to those patients who did
not. A second trial specifically evaluated undifferentiated carcino-
ma of the nasopharynx (Leong et al, 2004). EGFR expression
levels were ascertained in 75 patients diagnosed with undiffer-
entiated NPC. Rates of overexpression were reported at 83%. In
this cohort, the patients with EGFR overexpression did have a
more locally aggressive disease, but DFS and OS rates did not alter
significantly between the two groups. Given the finding of the high
prevalence of EGFR overexpression, a phase II study of cetuximab
(Erbitux, C-225) in combination with carboplatin for patients
with metastatic or recurrent NPC was undertaken (Chan et al,
2003). Of 60 patients, 56 screened were positive for EGFR
expression and enrolled in the trial. The overall response rate
was 17%, and partial response or stable disease accounted for
66%. Based on this preliminary data, EGFR is a viable target
for further clinical trials. Furthermore, a recent randomised
phase III trial of RT with or without cetuximab in patients
with locoregionally advanced non-nasopharyngeal squamous cell
cancers of the head and neck has shown a significant survival
benefit with the addition of cetuximab, and toxicity profile
was acceptable. This trial has definite implications for the
role of anti-EGFR agents in locally advanced NPC, and further
evaluations are needed to determine how best to incorporate
them into current standard chemoradiotherapy regimens (Bonner
et al, 2004).
Vascular endothelial growth factor is an angiogenic factor,
which contributes to angiogenesis and subsequent growth,
invasion and metastasis of tumours. Expression of VEGF has been
compared between tissue samples obtained from normal naso-
pharynx without tumour, nasopharyngeal benign tumours and
NPC: the rates of VEGF expression were 10, 40 and 80%,
respectively. As well, expression of VEGF in advanced disease
was increased with a statistical significance compared with those in
early-stage disease (Guang-Wu et al, 2000). The role of anti-VEGF
therapy has not been explored, but could serve as a potential target
in future studies.
A retrospective study of 49 patients with NPC assessed
the overexpression of HER2 and c-KIT (Bar-Sela et al, 2003).
c-KIT overexpression was found in 33% of the cases and was
associated with a positive Ebstein–Barr virus (EBV) status
(by EBER in situ hybridisation) in patients whose histology
showed nonkeratinising or undifferentiated carcinoma. These
cases were associated with a trend towards a better survival.
Whether or not a potential therapeutic role for inhibitors
of c-KIT such as imatinib mesylate exists remains unknown at
the present. In this same cohort of patients, HER2 overexpress-
ion was uniformly negative. This result differs from a Hong Kong
study of 78 Chinese patients with undifferentiated NPC (Ma
et al, 2003), in which HER2 overexpression was observed in 31%
of the patients and conferred an association with increased stage
of disease. Lastly, a study from Guangzhou in Southern China
performed both immunohistochemical and fluorescent in situ
hybridisation (FISH) analyses of HER2 in 45 cases of NPC. While
33% of patients had HER2 expression in tumour samples by
immunohistochemical staining, this did not correlate with clinical
outcome, and no significant alterations in gene copy number of
HER2 was detected by FISH (Yan et al, 2002). At the present, no
studies of trastuzumab or other HER2 inhibitors have been
reported in NPC.
EBV IN NPC AND IMMUNOTHERAPY
A clear association exists between EBV infection and NPC. EBV is
present in the cells of almost all primary and metastatic NPC,
regardless of tumour histology, extent of disease or patient
geographic location. It has been postulated that plasma EBV
DNA quantification can be useful to follow patients and predict
outcome of treatment (Lin et al, 2004). A recent study was
conducted to investigate the significance of plasma EBV DNA
concentrations in patients with advanced NPC. In all, 99 patients
were treated with neodjuvant cisplatin and 5-fluorouracil given
on alternate weeks for 10 weeks followed by RT therapy to a
total of 70–74Gy. Blood samples were obtained for measurement
of EBV DNA concentrations using real-time quantitative poly-
merase chain reaction. Samples were obtained 1 day prior to
beginning treatment, days 35 and 64 during neoadjuvant
chemotherapy, and 1 week after completion of RT. Forty healthy
volunteers, 20 patients cured of their disease for greater than
5 years and 19 patients with metastatic disease were used as
controls. At baseline, 94 of 99 patients with stage III and IV
disease, and all patients with metastatic disease had detectable
plasma EBV DNA. No healthy controls had detectable EBV
DNA. EBV DNA concentrations were significantly higher in the
group that subsequently relapsed following therapy vs the group
that remained in a clinical remission. Higher pretreatment EBV
DNA values corresponded to a decreased OS and DFS. Based on
this initial data, EBV DNA quantification seems promising as a
marker to monitor and predict treatment outcomes in patients
with advanced NPC.
Given this association of EBV and NPC, investigators
have evaluated a role for immunotherapy. In-depth studies
have established that NPC cells express two distinct EBV
latent membrane proteins, LMP-1 and LMP-2. These proteins
become attractive targets for adoptive immunotherapy. A phase I
study of EBV-specific cytotoxic T lymphocytes (CTL) was under-
taken in EBV-positive patients with advanced NPC. CTL were
generated and then infused into 10 patients. Four patients treated
in remission remained disease free 19–27 months after infusion.
Of six patients with refractory disease, two had complete
responses, one had a partial response, one had stable disease
and two had no response (Straathof et al, 2004). Except for
the development of increased swelling at the site of pre-existing
disease in one patient, CTL were generally well tolerated by
all patients. Based on the preliminary work, the adminis-
tration of CTL is feasible and is associated with significant
antitumour activity. Further studies utilising CTL should be
continued.
CONCLUSIONS
Based on the above data, a clear role for concomitant chemo-
radiotherapy followed by adjuvant chemotherapy has shown
statistically significant improvement in OS and DFS for all
histological types of locally advanced NPC. Neoadjuvant chemo-
therapy followed by concurrent chemoradiotherapy would be
a reasonable variation, since the maintenance of chemotherapy
dose intensity may be optimal using such a sequence. Further
treatment questions arise in the management of local and
distant failures. Intensity-modulated RT proves to be an improve-
ment in RT delivery, and in several phase II studies has initially
translated into better locoregional control and reduced toxicities.
In cases of recurrent or distant disease, the standard of care is
diverse.
Given the complex nature of this disease and the high risk
for development of distant failures, new treatment regimens need
to be developed for these patients. Exploration of the role of
targeted agents such as inhibitors of EGFR, VEGF, c-KIT and
HER2 are necessary. Adoptive immunotherapy with EBV-specific
CTL awaits further exploration. Certainly, the treatment strategies
for NPC will continue to change and evolve as a better
understanding is gained of the molecular and immune mechan-
isms that drive this disease.
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